中央控制室4
CCL22型
癌症研究
医学
免疫疗法
肿瘤微环境
索拉非尼
肝细胞癌
细胞毒性T细胞
免疫学
免疫系统
生物
趋化因子受体
趋化因子
生物化学
体外
作者
Yanan Gao,Maojun You,Junliang Fu,Meijie Tian,Xinyue Zhong,Chengzhi Du,Zhixian Hong,Zhenyu Zhu,Junliang Liu,Geoffrey J. Markowitz,Fu‐Sheng Wang,Pengyuan Yang
标识
DOI:10.1016/j.jhep.2021.08.029
摘要
Targeting regulatory T cells is a promising approach in cancer immunotherapy; however, severe autoimmunity can occur following systemic regulatory T cell loss. This could be avoided by selectively depleting intratumoral regulatory T cells. Herein, targeting intratumoral stem-like CCR4+ regulatory T cells helped to overcome sorafenib resistance and sensitize tumors to immune checkpoint blockade in mouse models of liver cancer. This approach could have wide clinical applicability.
科研通智能强力驱动
Strongly Powered by AbleSci AI